Home 
Bratislava Medical Journal 2019 Bratislava Medical Journal Vol.120, No.4, p.295–298, 2019
Bratislava Medical Journal 2019 Bratislava Medical Journal Vol.120, No.4, p.295–298, 2019
Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Ekologia - Ecology Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudba 2025Webshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Bratislava Medical Journal Vol.120, No.4, p.295–298, 2019 |
||
| Title: Nesfatin-1 and caspase-cleaved cytokeratin-18: Promising biomarkers for Alzheimer’s disease? | ||
| Author: M. Alpua, U. Kisa | ||
| Abstract: OBJECTIVES: To investigate the use of nesfatin-1 and caspase-cleaved cytokeratin-18 serum levels as biomarkers in Alzheimer’s disease. METHODS: The study group consisted of 39 patients with Alzheimer’s disease (AD) and 39 controls. Demographic characteristics including gender, age, body mass index, mini-mental status examination (MMSE) and duration of disease were recorded. The ELISA method was used to measure serum nesfatin-1 and CCCK-18 levels in serum samples. RESULTS: Serum nesfatin-1 levels were statistically significantly higher in the AD patient group than in controls. There was no significant difference between the groups with regards to serum CCCK-18 levels. Pearson analysis showed no significant correlation between serum nesfatin-1, serum CCCK-18 levels, mini–mental status examination and disease duration. CONCLUSION: This study proved that serum nesfatin-1 levels can be used as a biomarker in Alzheimer’s disease by showing a statistically significant high level of serum nesfatin-1 in patients with Alzheimer’s disease. This is the first study to suggest that nesfatin-1 can be used as a biomarker in Alzheimer’s disease. In addition, our study showed that CCCK-18 can be used as a prognostic biomarker for Alzheimer’s disease. Further comprehensive studies should be done to clarify the use of serum nesfatin-1 and CCCK-18 levels as biomarkers for Alzheimer disease (Tab. 3, Fig. 2, Ref. 25). |
||
| Keywords: nesfatin-1, CCCK-18, Alzheimer’s disease, mini-mental status examination | ||
| Published online: 26-Apr-2019 | ||
| Year: 2019, Volume: 120, Issue: 4 | Page From: 295, Page To: 298 | |
| doi:10.4149/BLL_2019_046 |
||
|
|
 download file |
|